Cencora (COR) displays strong promise as both a value and momentum stock. This bio-tech giant has consistently demonstrated robust financial performance, catapulting it as a top growth stock. However, its earnings growth rate lags behind at 23% CAGR. Despite some insider selling, institutions like the Principal Financial Group Inc. and Unigestion Holding SA have increased their stake. Large acquisition moves, including a $4.6B purchase of Retina Consultants, have bolstered its position in the industry. Q4 revenue soared 14.7% to $79.1B, despite challenges to EPS. Simultaneously, the company raised $1.8B in senior notes offerings to fund acquisitions and lowered its price target to $237 from $249 at Wells Fargo. While the stock did slide on uneven Q3 results and after the last earnings report, it soon hit a new high, reflecting its resilience. It recently received a consensus recommendation of 'moderate buy'. Overall, investors who invested in Cencora five years ago have gained 193%, and the current forecasts hint at a continuation of this robust growth. However, it's worth noting that despite strong earnings, Cencora's Q4 2024 EPS missed expectations.
Cencora COR News Analytics from Wed, 22 May 2024 07:00:00 GMT to Tue, 24 Dec 2024 07:43:12 GMT -
Rating 8
- Innovation 7
- Information 7
- Rumor 2
